Cempra (CEMP) Says CEM-101 Efficacy Comparable to Levofloxacin in CABP Following Phase 2 – StreetInsider.com

Cempra Inc. (Nasdaq: CEMP), reports that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101’s (solithromycin’s) efficacy to be comparable to …

Leave a Reply

Your email address will not be published.